Obstructive sleep apnoea and schizophrenia - A research agenda

Sleep Medicine Reviews

Volumn 17, Issue 5, 2013, Pages 357-365

  Kalucy, Megan J ^a   Grunstein, Ron ^a,b   Lambert, Timothy ^b   Glozier, Nicholas ^b  

^a The Woolcock Clinic   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CPAP; Metabolic syndrome; Obstructive sleep apnoea; Review; Schizophrenia; Sleep

Indexed keywords

ANXIETY DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BODY MASS; DAYTIME SOMNOLENCE; HEALTH PRACTITIONER; HUMAN; MEDLINE; MENTAL HEALTH SERVICE; MORBIDITY; NECK CIRCUMFERENCE; OBESITY; OROPHARYNX AIRWAY; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SLEEP DISORDERED BREATHING; SLEEP MEDICINE; SYSTEMATIC REVIEW;

CPAP; METABOLIC SYNDROME; OBSTRUCTIVE SLEEP APNOEA; REVIEW; SCHIZOPHRENIA; SLEEP;

BIOMEDICAL RESEARCH; COMORBIDITY; HUMANS; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; SLEEP APNEA, OBSTRUCTIVE;

EID: 84881260896     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2012.10.003     Document Type: Review

References (112)

1. Saha S., Chant D., Welham J., McGrath J. Asystematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
2. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 364:2063-2072.
3. Lambert T. Multidimensional approaches to incomplete recovery in psychosis. Therapy-resistant schiziophrenia 2010, 87-113. Karger, Basel. H. Elkis, H. Meltzer (Eds.).
4. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
5. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009, 35:528-548.
6. Dixon L.B., Dickerson F., Bellack A.S., Bennett M., Dickinson D., Goldberg R.W., et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010, 36:48-70.
7. Benson K.L. Sleep in schizophrenia: impairments, correlates, and treatment. Psychiatr Clin North Am 2006, 29:1033-1045.
8. Birchwood M., Spencer E., McGovern D. Schizophrenia: early warning signs. Adv Psychiatr Treat 2000, 6:93-101.
9. Chouinard S., Poulin J., Stip E., Godbout R. Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr Bull 2004, 30:957-967.
10. Fitzgerald P.B. The role of early warning symptoms in the detection and prevention of relapse in schizophrenia. Aust N Z J Psychiatry 2001, 35:758-764.
11. Wulff K., Dijk D.-J., Middleton B., Foster R.G., Joyce E.M. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 2012, 200:308-316.
12. Ferrarelli F., Huber R., Peterson M., Massimini M., Murphy M., Riedner B., et al. Reduced sleep spindle activity in schizophrenia patients. Am J Psychiatry 2007, 164:483-492.
13. Ferrarelli F., Peterson M.J., Sarasso S., Riedner B.A., Murphy M.J., Benca R.M., et al. Thalamic dysfunction in schizophrenia suggested by whole-night deficits in slow and fast spindles. Am J Psychiatry 2010, 167:1339-1348.
14. Keshavan M.S., Miewald J., Haas G., Sweeney J., Ganguli R., Reynolds C.F. Slow-wave sleep and symptomatology in schizophrenia and related psychotic disorders. JPsychiatr Res 1995, 29:303-314.
15. Benson K.L., Sullivan E.V., Lim K.O., Lauriello J., Zarcone V.P., Pfefferbaum A. Slow wave sleep and computed tomographic measures of brain morphology in schizophrenia. Psychiatry Res 1996, 60:125-134.
16. Lauer C.J., Krieg C. Slow-wave sleep and ventricular size: a comparative study in schizophrenia and major depression. Biol Psychiatry 1998, 44:121-128.
17. Göder R., Boigs M., Braun S., Friege L., Fritzer G., Aldenhoff J.B., et al. Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia. JPsychiatr Res 2004, 38:591-599.
18. Marshall L., Helgadóttir H., Mölle M., Born J. Boosting slow oscillations during sleep potentiates memory. Nature 2006, 444:610-613.
19. Manoach D.S., Stickgold R. Does abnormal sleep impair memory consolidation in schizophrenia?. Front Hum Neurosci 2009, 3. Article 21.
20. Lee E.K., Douglass A.B. Sleep in psychiatric disorders: where are we now?. Can J Psychiatry 2010, 55:403-412.
21. Goldberg T.P., Gomar J.M. Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry 2009, 166:631-634.
22. Lambert T., Velakoulis D., Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003, 178(Suppl.):S67-S70.
23. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009, 119:4-14.
24. Parks J., Svendsen D., Singer P., Foti M. Morbidity and mortality in people with serious mental illness 2006, National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council.
25. Chang C.-K., Hayes R.D., Perera G., Broadbent M.T.M., Fernandes A.C., Lee W.E., et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental mealth care case register in London. PLoS ONE 2011, 6:e19590.
26. Bell R.C., Farmer S., Ries R., Srebnik D. Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatr Serv 2009, 60:1686-1689.
27. Bradley T.D., Floras J.S. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009, 373:82-93.
28. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001, 46:549-555.
29. Thakore J.H., Mann J.N., Vlahos H., Martin A., Reznek R. Increased visceral fat distribution in drug-naive and drug -free patients with schizophrenia. Int J Obes Relat Metab Disord 2002, 26:137-141.
30. Ryan M.C.M., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004, 74:1999-2008.
31. Mukherjee S., Schnur D., Reddy R. Family history of type 2 diabetes in schizoprhenic patients. Lancet 1989, 333:495.
32. Ryan M.C.M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
33. Thakore J.H. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry 2004, 184:s76-s79.
34. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007, 24:481-485.
35. Holt R.I.G., Peveler R.C. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006, 8:125-135.
36. Morselli L., Leproult R., Balbo M., Spiegel K. Role of sleep duration in the regulation of glucose metabolism and appetite. Best Pract Res Clin Endocrinol Metab 2010, 24:687-702.
37. Moons T., Claes S., Martens G.J., Peuskens J., Van Loo K.M., Van Schijndel J.E., et al. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs. Schizophr Res 2011, 125:187-193.
38. Robillard R., Rogers N., Whitwell B., Lambert T. Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven review. Clin Psychopharmacol Neurosci 2012, 10:1-12.
39. Lawrence D., Kisely S. Review: inequalities in healthcare provision for people with severe mental illness. JPsychopharmacol (Oxf) 2010, 24:61-68.
40. De Hert M., Correll C.U., Bobes J., Cetkovich-Bakmas M., Cohen D., Asai I., et al. Physical illness in patients with severe mental disorder. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10:52-77.
41. Lambert T.J.R., Newcomer J.W. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009, 190(4 Suppl.):S39-S42.
42. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. JClin Psychiatry 2007, 68(Suppl. 4):8-13.
43. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085.
44. Kim S., Huang A., Snowman A., Teuscher C., Snyder S. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007, 104:3456-3459.
45. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
46. Malhotra A., White D.P. Obstructive sleep apnoea. Lancet 2002, 360:237-245.
47. Vgontzas A.N., Bixler E.O., Chrousos G.P. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005, 9:211-224.
48. Iskander I., Hall A.P., O'Reilly J., Barnett A., Allen M., Andrews R., et al. Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. Diabetes Obes Metab 2009, 11:733-741.
49. Nock N., Li L., Larkin E., Patel S., Redline S. Empirical evidence for "syndrome Z": a hierarchical 5-factor model of the metabolic syndrome incorporating sleep disturbance measures. Sleep 2009, 32:615-622.
50. Sleep disorders and sleep deprivation: an unmet public health problem 2006, The National Academies Press, Washington, DC. H.R. Colten, B.M. Altebogt (Eds.).
51. Hardinge M. Obstructive sleep apnoea. Medicine 2008, 36:237-241.
52. Young T., Evans L., Finn L., Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 1997, 20:705-706.
53. Kapur V., Strohl K.P., Redline S., Iber C., O'Connor G., Nieto J. Underdiagnosis of sleep apnea syndrome in U.S. communities. Sleep Breath 2002, 6:49-54.
54. Chung S., Yoon I., Lee C., Kim J. The association of nocturnal hypoxemia with arterial stiffness and endothelial dysfunction in male patients with Obstructive Sleep Apnea Syndrome. Respiration 2010, 79:363-369.
55. Mehra R., Xu F., Babineau D., Tracy R., Jenny N., Patel S., et al. Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study. Am J Respir Crit Care Med 2010, 182:826.
56. Redline S., Yenokyan G., Gottlieb D., Shahar E., O'Connor G., Resnick H., et al. Obstructive sleep apnea-hypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med 2010, 182:269.
57. Devulapally K., Pongonis R., Khayat R. OSA: the new cardiovascular disease. Heart Failure Reviews 2009, 14:155.
58. O'Connor G., Caffo B., Newman A., Quan S., Rapoport D., Redline S., et al. Prospective study of sleep-disordered breathing and hypertension: the sleep heart health study. Am J Respir Crit Care Med 2009, 179:1159.
59. Mehra R., Benjamin E.J., Shahar E., Gottlieb D.J., Nawabit R., Kirchner H.L., et al. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med 2006, 173:910.
60. Aronsohn R., Whitmore H., Van Cauter E., Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 2010, 181:507.
61. Muraki I., Tanigawa T., Yamagishi K., Sakurai S., Ohira T., Imano H., et al. Nocturnal intermittent hypoxia and the development of type 2 diabetes: the Circulatory Risk in Communities Study (CIRCS). Diabetologia 2010, 53:481.
62. Aloia M.S., Arnedt J.T., Davis J.D., Riggs R.L., Byrd D. Neuropsychological sequelae of obstructive sleep apnea-hypopnea syndrome: A critical review. JInt Neuropsychol Soc 2004, 10:772-785.
63. Rodenstein D. Sleep apnea: traffic and occupational accidents - individual risks, socioeconomic and legal implications. Respiration 2009, 78:241.
64. Lindberg E.V.A., Carter N.E.D., Gislason T., Janson C. Role of snoring and daytime sleepiness in occupational accidents. Am J Respir Crit Care Med 2001, 164:2031-2035.
65. Vakulin A., Baulk S.D., Catcheside P.G., Antic N.A., van den Heuvel C.J., Dorrian J., et al. Effects of alcohol and sleep restriction on simulated driving performance in untreated patients with obstructive sleep apnea. Ann Intern Med 2009, 151:447-455.
66. Ohayon M.M. The effect of breathing-related sleep disorders on mood disturbances in the general population. JClin Psychiatry 2003, 64:1195-1200.
67. Schröder C., O'Hara R. Depression and obstructive sleep apnea (OSA). Ann Gen Psychiatry 2005, 4:13.
68. Sharafkhaneh A., Giray N., Richardson P., Young T., Hirshkowitz M. Association of psychiatric disorders and sleep apnea in a large cohort. Sleep 2005, 28:1405-1411.
69. Monti J.M., Monti D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 2004, 8:133-148.
70. Haffmans P.M., Hoencamp E., Knegtering H.J. van Heycop ten Ham BF. Sleep disturbance in schizophrenia. Br J Psychiatry 1994, 165:697-698.
71. Young T., Peppard P.E., Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002, 165:1217-1239.
72. Winkelman J.W. Schizophrenia, obesity, and obstructive sleep apnea. JClin Psychiatry 2001, 62:8-11.
73. Boufidis S., Kosmidis M.H., Bozikas V.P., Daskalopoulou-Vlahoyianni E., Pitsavas S., Karavatos A. Treatment outcome of Obstructive Sleep Apnea Syndrome in a patient with schizoprhenia: case report. Int J Psychiatry Med 2003, 33:305.
74. McMillan K.B., Enns M.M.F., Cox B.P., Sareen J.M.F. Comorbidity of axis I and II mental disorders with schizophrenia and psychotic disorders: findings from the National epidemiologic survey on alcohol and related conditions. Can J Psychiatry 2009, 54:477.
75. McClave A., McKnight-Eily Davis S., Dube S. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 national health interview survey. Am J Public Health 2010, 100:2464-2472.
76. Engleman H., Joffe D. Neuropsychological function in obstructive sleep apnoea. Sleep Med Rev 1999, 3:59-78.
77. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-III-R 1987, American Psychiatric Association, Washington, D.C., Revised. 3rd ed.
78. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association. 4th ed.
79. World Health Organization The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines 1992, World Health Organization, Geneva.
80. Benson K.L., Zarcone V.P.J. Sleep abnormalities in schizophrenia and other psychotic disorders. Review of psychiatry 1994, vol. 13:677-705. American Psychiatric Press, Washington, chapter 27. J. Oldham, M. Riba (Eds.).
81. Takahashi K.-I., Shimizu T., Sugita T. Prevalence of sleep-related respiratory disorders in 101 schizophrenic inpatients. Psychiatry Clin Neurosci 1998, 52:229-231.
82. Ryan P.J., Hilton M.F., Boldy D.A., Evans A., Bradbury S., Sapiano S., et al. Validation of British Thoracic Society guidelines for the diagnosis of the sleep apnoea/hypopnoea syndrome: can polysomnography be avoided?. Thorax 1995, 50:972-975.
83. Ancoli-Israel S., Martin J., Jones D.W., Caligiuri M., Patterson T., Harris M.J., et al. Sleep-disordered breathing and periodic limb movements in sleep in older patients with schizophrenia. Biol Psychiatry 1999, 45:1426-1432.
84. Haque M.F., Anwar M.M., Crowe C., Brophy J., Stokes M. Undiagnosed obstructive sleep apnoea in schizophrenia. JSleep Res 2008, 17:S150.
85. Flemons W.W., Douglas N.J., Kuna S.T., Rodenstein D.O., Wheatley J. Access to diagnosis and treatment of p[atients with suspected sleep apnea. Am J Respir Crit Care Med 2004, 169:668-672.
86. Mitchell A.J., Malone D., Doebbeling C.C. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparitice studies. Br J Psychiatry 2009, 194:491-499.
87. Rishi M.A., Shetty M., Wolff A., Amoateng-Adjepong Y., Manthous C.A. Atypical antipsychotic medications are independently associated with severe obstructive sleep apnea. Clin Neuropharmacol 2010, 33:109-113.
88. Freudenmann R.W., Süssmuth S.D., Wolf R.C., Stiller P., Schönfeldt-Lecuona C. Respiratory dysfunction in sleep apnea associated with quetiapine. Pharmacopsychiatry 2008, 41:119-121.
89. Lalley P.M. D1/D2-dopamine receptor agonist dihydrexidine stimulates inspiratory motor output and depresses medullary expiratory neurons. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1829-R1836.
90. Giles T., Lasserson T., Smith B., White J., Wright J., Cates C. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2008.
91. Weaver T.E., Grunstein R.R. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008, 5:173-178.
92. Catcheside P.G. Predictors of continuous positive airway pressure adherence. F1000 Med Rep 2010, 2(70). [Internet] Available from:, [accessed 15.04.11]. http://f1000.com/reports/medicine/content/2/70.
93. Smith I., Nadig V., Lasserson T. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database of Syst Rev 2009.
94. Wirshing D.A., Pierre J.M., Wirshing W.C. Sleep apnea associated with antipsychotic-induced obesity. JClin Psychiatry 2002, 63:369-370.
95. Karanti A., Landén M. Treatment refractory psychosis remitted upon treatment with continuous positive airway pressure: a case report. Psychopharmacol Bull 2007, 40:113-117.
96. Bottlender R., Möller H.J. Negative symptoms due to sleep apnea syndrome in a patient with a delusional disorder. Eur Psychiatry 1999, 14:352.
97. Chiner E., Arriero J.M., Signes-Costa J. Marco J. Acute psychosis after CPAP treatment in a schizophrenic patient with sleep apnoea-hypopnoea syndrome. Eur Respir J 2001, 17:313-315.
98. Martin P.R., Lefebvre A.M. Surgical treatment of sleep-apnea-associated psychosis. Can Med Assoc J 1981, 124:979.
99. Lee S., Chiu H.F.K., Chen C.-N. Psychosis in sleep apnoea. Aust N Z J Psychiatry 1989, 23:571-573.
100. Berrettini W.H. Paranoid psychosis and sleep apnea syndrome. Am J Psychiatry 1980, 137:493-494.
101. Sunitha C., Kumar S. Obstructive sleep apnea and its management. Indian J Dent Res 2010, 21:119.
102. Morein-Zamir S., Turner D.C., Sahakian B.J. Areview of the effects of modafinil on cognition in schizophrenia. Schizophr Bull 2007, 33:1298-1306.
103. Barnes T.R. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. JPsychopharmacol 2011, 25:567-620.
104. Sánchez A.I., Martínez P., Miró E., Bardwell W.A., Buela-Casal G. CPAP and behavioral therapies in patients with obstructive sleep apnea: effects on daytime sleepiness, mood, and cognitive function. Sleep Med Rev 2009, 13:223-233.
105. Platón M.J.R., Sierra J.E. Changes in psychopathological symptoms in sleep apnea patients after treatment with nasal continuous positive airway pressure. Int J Neurosci 1991, 62:173-195.
106. Canessa N., Castronovo V., Cappa S., Aloia M., Marelli S., Falini A., et al. Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. Am J Respir Crit Care Med 2011, 183:1419.
107. Martínez-García M., Soler-Cataluña J., Ejarque-Martínez L., Soriano Y., Román-Sánchez P., Illa F., et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. Am J Respir Crit Care Med 2009, 180:36-41.
108. Dolder C., Lacro J., Jeste D. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003, 65:156-162.
109. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. JPsychiatr Pract 2010, 16:34-45.
110. Tuomilehto H.P.I., Seppa J.M., Partinen M.M., Peltonen M., Gylling H., Tuomilehto J.O.I., et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009, 179:320-327.
111. De Hert M., Cohen D., Bobes J., Cetkovich-Bakmas M., Leucht S., Ndetei D.M., et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011, 10:138-151.
112. Weaver I.C.G., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004, 7:847-854.